menu
    • menu
    [{"orgOrder":0,"company":"Neuroplast","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"NETHERLANDS","productType":"Cell & Gene Therapy","year":"2019","type":"Inapplicable","leadProduct":"Autologous Fresh Stem Cell","moa":"Undisclosed","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II\/ Phase III","graph3":"Neuroplast","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Neuroplast \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Neuroplast \/ Undisclosed"},{"orgOrder":0,"company":"Neuroplast","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"NETHERLANDS","productType":"Cell & Gene Therapy","year":"2019","type":"Inapplicable","leadProduct":"Autologous Fresh Stem Cell","moa":"Undisclosed","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II\/ Phase III","graph3":"Neuroplast","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Neuroplast \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Neuroplast \/ Undisclosed"},{"orgOrder":0,"company":"Neuroplast","sponsor":"Lumana Invest","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"NETHERLANDS","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"Autologous Fresh Stem Cell","moa":"Undisclosed","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II\/ Phase III","graph3":"Neuroplast","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Neuroplast \/ Lumana Invest","highestDevelopmentStatusID":"9","companyTruncated":"Neuroplast \/ Lumana Invest"},{"orgOrder":0,"company":"Neuroplast","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"NETHERLANDS","productType":"Cell & Gene Therapy","year":"2023","type":"Inapplicable","leadProduct":"Neuro Cell","moa":"Undisclosed","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II\/ Phase III","graph3":"Neuroplast","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Injection","sponsorNew":"Neuroplast \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Neuroplast \/ Undisclosed"}]

    Find Clinical Drug Pipeline Developments & Deals by Neuroplast

    Menu

    Neuroplast

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Neuroplast

                            Netherlands arrow
                            Global ChemShow
                            Not Confirmed

                            Neuroplast

                            Netherlands arrow
                            Global ChemShow
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Neuro Cell

                            Therapeutic Area : Trauma (Emergency, Injury, Surgery)

                            Study Phase : Phase II/ Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Neuroplast Successfully Completes Patient Inclusion of Phase II Clinical Trial for Traumatic Spinal Cord Injur...

                            Details : Neuro-Cells® is a transformative platform treatment under GMP. It contains a non-substantially manipulated bone marrow-derived integrated mixture of stem cells including hematopoietic and mesenchymal stem cells, investigated for traumatic spinal cord in...

                            Product Name : Undisclosed

                            Product Type : Cell & Gene Therapy

                            Upfront Cash : Inapplicable

                            September 07, 2023

                            Lead Product(s) : Neuro Cell

                            Therapeutic Area : Trauma (Emergency, Injury, Surgery)

                            Highest Development Status : Phase II/ Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Neuroplast

                            Netherlands arrow
                            Global ChemShow
                            Not Confirmed

                            Neuroplast

                            Netherlands arrow
                            Global ChemShow
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Autologous Fresh Stem Cell

                            Therapeutic Area : Trauma (Emergency, Injury, Surgery)

                            Study Phase : Phase II/ Phase III

                            Sponsor : Lumana Invest

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Neuroplast Receives Second Orphan Medicinal Product Designation for Neuro-Cells®, Paving the Way for Applicat...

                            Details : Neuro-Cells (Autologous Fresh Stem Cells) contains non-substantially manipulated bone marrow-derived hematopoietic and mesenchymal stem cells, manufactured from a patient's own bone marrow (donor and receiver are the same person).

                            Product Name : Neuro Cell

                            Product Type : Cell & Gene Therapy

                            Upfront Cash : Inapplicable

                            September 08, 2022

                            Lead Product(s) : Autologous Fresh Stem Cell

                            Therapeutic Area : Trauma (Emergency, Injury, Surgery)

                            Highest Development Status : Phase II/ Phase III

                            Sponsor : Lumana Invest

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Neuroplast

                            Netherlands arrow
                            Global ChemShow
                            Not Confirmed

                            Neuroplast

                            Netherlands arrow
                            Global ChemShow
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Autologous Fresh Stem Cell

                            Therapeutic Area : Trauma (Emergency, Injury, Surgery)

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Safety Stem Cells in Spinal Cord Injury

                            Details : Neuro-Cells (Autologous Fresh Stem Cell) is a Cell and Gene Therapy drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Spinal Cord Injuries.

                            Product Name : Neuro-Cells

                            Product Type : Cell & Gene Therapy

                            Upfront Cash : Inapplicable

                            December 19, 2019

                            Lead Product(s) : Autologous Fresh Stem Cell

                            Therapeutic Area : Trauma (Emergency, Injury, Surgery)

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Neuroplast

                            Netherlands arrow
                            Global ChemShow
                            Not Confirmed

                            Neuroplast

                            Netherlands arrow
                            Global ChemShow
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Autologous Fresh Stem Cell

                            Therapeutic Area : Trauma (Emergency, Injury, Surgery)

                            Study Phase : Phase II/ Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Stem Cells in Spinal Cord Injury

                            Details : Neuro-Cells (Autologous Fresh Stem Cell) is a Cell and Gene Therapy drug candidate, which is currently being evaluated in phase II/ phase III clinical studies for the treatment of Spinal Cord Injuries.

                            Product Name : Neuro-Cells

                            Product Type : Cell & Gene Therapy

                            Upfront Cash : Inapplicable

                            May 02, 2019

                            Lead Product(s) : Autologous Fresh Stem Cell

                            Therapeutic Area : Trauma (Emergency, Injury, Surgery)

                            Highest Development Status : Phase II/ Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth